



Applied Pharmacoeconomic and Outcomes Research Forum

March 7th 2016



UNIVERSITY *of* CALIFORNIA
SAN DIEGO

SKAGGS SCHOOL *of* PHARMACY
and PHARMACEUTICAL SCIENCES

12 Forums and TEN Years ...

1. AMCP Dossiers: Useful for Decision Making or Not? A Debate
2. Biologics: Drawing (or Crossing) the line of Cost vs. Benefit: A Case in Oncology
3. Quality Adjusted Life Years (QALY' s) for Decision Making: Views from Canada & the US
4. Using Large Databases to Inform Decision Making: Experience in Three Health Care Systems
5. Real World Data for Decision Making: Moving Beyond Clinical Trials
6. Pharmacoeconomics of Pharmacogenomics
7. Pharmacoeconomics & Pricing: Now & After Health Care Reform
8. What is the Business Case for Quality Improvement Initiatives?
9. Specialty Pharmacy Distribution Channels & Processes: Challenges & Opportunities Today & Under Health Care Reform
10. Biosimilars: Challenges and Opportunities for All.
11. Patient Reported Outcomes: Useful for Whom?
- 12. Health Services Research: Applications & Challenges Across Healthcare Systems**

Forum Objectives

- Discuss commonly encountered obstacles to conducting or utilizing results of PE studies for decision making
- Explore solutions from various perspectives
 - Managed Care
 - Government
 - Pharmaceutical/Biotech Firms
 - Medical Centers
 - Academia
- Create an environment & foundation to foster larger PE/Outcomes Research Interest

Group



Steering Committee

Michael S. Broder MD, MSHS

Partnership for Health Analytic Research

Charles Daniels, RPh, PhD

UCSD Health Department of Pharmacy

Jan D. Hirsch, RPh, PhD

*UCSD, Skaggs School of
Pharmacy & Pharmaceutical Sciences*

Mirta Millares, PharmD, FCSHP, FASHP

Kaiser Permanente – CA Region

Anthony P. Morreale, Pharm.D., MBA, BCPS

PBM Services, Department of Veterans Affairs

Michael Pollock

PPD

Robert Schoenhaus, PharmD

Sharp HealthCare

Sponsors - Thanks!

PE Forum Sponsorship Fund




Exhibitors



Pharmaceutical Industries Ltd.



***Health Services Research
Applications & Challenges Across
Healthcare Systems***



Quiz Time!

Smart Phones Down

Laptops & Tablets Closed

Pharma Trivia

1. According to the World Health Organization, as of 2011, how many different types of diseases and related health problems exist?

- a. 823
- b. 12,420
- c. 101,222



Pharma Trivia

1. According to the World Health Organization, as of 2011, how many different types of diseases and related health problems exist?

a. 823

b. 12,420

c. 101,222



Pharma Trivia

2. Which state employs the most people directly involved with drug research & development?
- a. California
 - b. New Jersey
 - c. Massachusetts
 - d. New York

Pharma Trivia

2. Which state employs the most people directly involved with drug research & development?

- a. California
- b. New Jersey
- c. Massachusetts
- d. New York



Pharma Trivia

2. Which state employs the most people directly involved with drug research & development?

28,000 (2010)

- a. California
- b. New Jersey
- c. Massachusetts
- d. New York



Pharma Trivia

3. How many clinical studies are being conducted worldwide according to clinicaltrials.gov?

- a. 28,455
- b. 78,333
- c. 139,372
- d. 205,201



Pharma Trivia

3. How many clinical studies are being conducted worldwide according to clinicaltrials.gov?

- a. 28,455
- b. 78,333
- c. 139,372
- d. 205,201



Pharma Trivia

3. How many clinical studies are being conducted worldwide according to clinicaltrials.gov?

- a. 28,455
- b. 78,333
- c. 139,372
- d. 205,201

In 192 countries.



Pharma Trivia

4. How much higher is the average wage for bioscience workers compared to other private sector employees?

- a. 45%
- b. 79%
- c. 90%
- d. 110%



Pharma Trivia

4. How much higher is the average wage for bioscience workers compared to other private sector employees?

- a. 45%
- b. 79%
- c. 90%
- d. 110%



Pharma Trivia

4. How much higher is the average wage for bioscience workers compared to other private sector employees?

a. 45%

b. 79%

c. 90%

d. 110%

\$82,697 (2010)



Pharma Trivia

5. Of the drugs in the FDA's Orange Book (i.e., list of approved drugs), what percentage have generic counterparts?

- a. 32%
- b. 79%
- c. 90%
- d. 110%



Pharma Trivia

5. Of the drugs in the FDA's Orange Book (i.e., list of approved drugs), what percentage have generic counterparts?

a.32%

b.79%

c.90%

d.110%



Pharma Trivia

5. Of the drugs in the FDA's Orange Book (i.e., list of approved drugs), what percentage have generic counterparts?

a. 32%

b. 79%

c. 90%

d. 110%

10,072



Pharma Trivia

More after the Break!



Agenda

Overview Health Services Research Umbrella & Inclusion of Pharmacoeconomic Principles

Anthony P Morreale, PharmD, MBA, BCPS

Assistant Chief Consultant for Clinical Pharmacy Services and Healthcare Services Research
Pharmacy Benefits Management, Department of Veterans Affairs

Perspectives and Case Examples

Integrated Healthcare System

Heather Ourth, Pharm.D., BCPS, CGP

Program Manager: Clinical Pharmacy Practice Program and Outcomes Assessment
Pharmacy Benefits Management, Department of Veterans Affairs

Medical Center

Katie Derry, Pharm.D., BCPS

Pharmacy Specialist, Clinical Pharmacoeconomics and Outcomes
UC San Diego Health System

Medical Group

Andrea De Coro, PharmD

Executive Director, Clinical Pharmacy Services and Performance Improvement
MemorialCare Medical Foundation

Pharma Trivia

6. In 1667, a human received one of the first blood transfusions. What was the source of the blood?

- a. Lamb
- b. Rabbit
- c. Rat
- d. Dog



Pharma Trivia

6. In 1667, a human received one of the first blood transfusions. What was the source of the blood?

- a. Lamb
- b. Rabbit
- c. Rat
- d. Dog



Pharma Trivia

6. In 1667, a human received one of the first blood transfusions. What was the source of the blood?

- a. Lamb
- b. Rabbit
- c. Rat
- d. Dog



Pharma Trivia

7. The first of which class of drug was extracted from the venom of the Brazilian Arrow-headed viper?

- a. ARB
- b. 5HT3
- c. NNRTI
- d. ACE



Pharma Trivia

7. The first of which class of drug was extracted from the venom of the Brazilian Arrow-headed viper?

- a. ARB
- b. 5HT3
- c. NNRTI
- d. ACE



Angiotensin-Converting Enzyme Inhibitors – from bradykinin

Pharma Trivia

8. The biotech age began in 1973, when Stanley Cohen & Genentech founder Herbert Boyer inserted DNA from an animal into E. coli bacteria. What was the animal?
- a. Frog
 - b. Newt
 - c. Mouse
 - d. Rabbit

Pharma Trivia

8. The biotech age began in 1973, when Stanley Cohen & Genentech founder Herbert Boyer inserted DNA from an animal into E. coli bacteria. What was the animal?

- a. Frog
- b. Newt
- c. Mouse
- d. Rabbit



Pharma Trivia

8. The biotech age began in 1973, when Stanley Cohen & Genentech founder Herbert Boyer inserted DNA from an animal into E. coli bacteria. What was the animal?

- a. Frog
- b. Newt
- c. Mouse
- d. Rabbit



**African
Clawed
Frog**

Pharma Trivia



9. Warfarin was discovered in clover.
What is it named for?

- a. Willamette American River Fortune
- b. Wharf Alliance of Research Federation
- c. Wisconsin Alumni Research Foundation

Pharma Trivia



9. Warfarin was discovered in clover.
What is it named for?

- a. Willamette American River Fortune
- b. Wharf Alliance of Research Federation
- c. Wisconsin Alumni Research Foundation



Pharma Trivia

10. Cyclosporine was discovered partly as a result of what travel policy at a large Pharma company?
- a. Digging on location
 - b. Collecting hotel soaps
 - c. Tasting local wines
 - d. Using airport shuttles

Pharma Trivia

10. Cyclosporine was discovered partly as

a result of what travel policy at a large

Pharma company?

- a. Digging on location
- b. Collecting hotel soaps
- c. Tasting local wines
- d. Using airport shuttles



Pharma Trivia

10. Cyclosporine was discovered partly as

a result of what travel policy,  and a large

Pharma company?

- a. Digging on location
- b. Collecting hotel soaps
- c. Tasting local wines
- d. Using airport shuttles



Pharma Trivia

10. Cyclosporine was discovered partly as

a result of what travel policy,  and a large

Pharma company?

- a. Digging on location
- b. Collecting hotel soaps
- c. Tasting local wines
- d. Using airport shuttles



Agenda

Overview Health Services Research Umbrella & Inclusion of Pharmacoeconomic Principles

Anthony P Morreale, PharmD, MBA, BCPS

Assistant Chief Consultant for Clinical Pharmacy Services and Healthcare Services Research
Pharmacy Benefits Management, Department of Veterans Affairs

Perspectives and Case Examples

Integrated Healthcare System

Heather Ourth, Pharm.D., BCPS, CGP

Program Manager: Clinical Pharmacy Practice Program and Outcomes Assessment
Pharmacy Benefits Management, Department of Veterans Affairs

Medical Center

Katie Derry, Pharm.D., BCPS

Pharmacy Specialist, Clinical Pharmacoeconomics and Outcomes
UC San Diego Health System

Medical Group

Andrea De Coro, PharmD

Executive Director, Clinical Pharmacy Services and Performance Improvement
MemorialCare Medical Foundation